ALS research wins big bucks with $313M in new US government funding

The U.S.-based advocacy group I AM ALS has secured $313 million in new federal funding for Push for Progress, an effort the nonprofit launched in late 2025 to accelerate research and expand access to treatments for amyotrophic lateral sclerosis (ALS). In a press release announcing the…

As I cuddle my newborn granddaughter in my arms at the hospital, I murmur to her, telling her that she is perfect and I love her. I tell her about her aunts, uncles, and cousins who are excited to meet her. Despite the impact of bulbar-onset ALS on my…

No U.S. state earned the highest possible score on the ALS Association‘s annual ALS State Policy Report Cards for policies supporting people with amyotrophic lateral sclerosis (ALS) this year, and several averaged failing grades. The report cards are designed to provide a…

Over the past few weeks, it’s been unseasonably and brutally cold here in Maryland, where I live. A severe storm coated much of the state with fluffy snow, then several inches of hazardous ice that hasn’t melted. This might be pretty if it weren’t so treacherous, leading to more accidents…

Glycogen, an inflammatory sugar molecule produced by certain gut bacteria, may play a key role in driving amyotrophic lateral sclerosis (ALS), a study found. Treatments to degrade glycogen reduced inflammation and extended survival in an animal model of the disease, and clinical trials to test this approach in people…

Last night, I had a dream in which my husband, Todd, did not have ALS. It was a bit of sweet respite from my day-to-day life, and I woke up missing that old version of us. In real life, I am Todd’s caregiver. He is completely paralyzed and needs…

ALS ONE, a Massachusetts-based nonprofit focused on accelerating research into amyotrophic lateral sclerosis (ALS), will soon become part of the ALS Network, an ALS advocacy organization that serves people with ALS in California and Hawaii. “This moment marks a real inflection point for the ALS community,” Sheri…

In the 40-plus years rollators have been around, few design modifications have been made. The changes that have been made target an older demographic. But today’s rollator users don’t just live in nursing homes — we are traveling, attending social events, and seeking designs that match our lifestyles. If you…

Elite athletes, military veterans, first responders, and other high performers have a significantly higher risk of developing amyotrophic lateral sclerosis (ALS) than the general population, and a new study aims to find out why. The initiative, Champion Insights, is seeking up to…

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS). The open-label PIONEER-ALS (NCT07287397) is enrolling up to 12 adults with ALS at sites in the U.S. and Europe. They will…